盟科药业：公司拟定增易主 第一大股东投反对票

Core Points - Genie's Pharma, the largest shareholder of Amgen Pharmaceutical, holds 71.57 million shares, accounting for 10.92% of the total shares [1] - Genie Pharma opposes several proposals at the upcoming extraordinary general meeting, including a plan for Amgen to issue shares to HaiJing Pharmaceutical to raise up to 1.033 billion yuan [1] - If the share issuance is completed, HaiJing Pharmaceutical will hold 20% of Amgen's shares and nominate 5 out of 9 board members, making it the controlling shareholder [1] Proposal Details - The proposal involves Amgen raising funds through a specific share issuance plan, which has raised concerns from Genie Pharma [1] - Genie Pharma's objections include uncertainties regarding the funding from HaiJing Pharmaceutical, potential loss of independence for Amgen, and doubts about the synergy in research and development [1] - Concerns are also raised about HaiJing Pharmaceutical's compliance history and management capabilities, which could impact Amgen's operations [1]